Men with advanced prostate cancer can benefit from Taxotere (docetaxel) chemotherapy

Increases life expectancy, reduces pain, and improves quality of life

 

Update, Nov 4: European Union approves Taxotere (docetaxel) for treatment of prostate cancer . . .

Toronto /PSA Rising/ October 6, 2004 — An international study led by a Canadian researcher shows that men with advanced, incurable prostate cancer can survive an average of three months longer and face less intense symptoms when offered a taxane chemotherapy treatment for prostate cancer.

To be published tomorrow in Oct 6 edition of The New England Journal of Medicine, the study involved 24 countries and over two years tracked more than 1,000 patients with advanced hormone-refractory prostate cancer.

The patients were randomly divided into three groups, with one group receiving the standard chemotherapy (mitoxantrone), while the other two groups received docetaxel brand name Taxotere) either every three weeks or weekly. All three groups received low daily doses of prednisone.

Researchers looked at several outcome measures survival, pain relief, improved quality of life, and the amount of PSA in the patients' blood, which usually indicates the amount of prostate cancer in a prostate cancer patient's body.

In all these measures, men who received docetaxel administered every three weeks did better than those who received mitoxantrone, and it improved survival by an average of three months. There was no significant difference in survival between those patients receiving docetaxel weekly and those receiving mitoxantrone.

"The new treatment of docetaxel results in many patients feeling better and living a few months longer," said Dr. Ian Tannock, the study's lead author and medical oncologist at Princess Margaret Hospital, senior scientist with Ontario Cancer Institute, and professor with the University of Toronto. "As a result, we are recommending docetaxel every three weeks with daily prednisone as the new standard of treatment for many patients with advanced hormone-refractory prostate cancer."

Prostate cancer is the most common cancer in men. One in eight Canadian and US men will develop the disease during their lifetime, and most cases are diagnosed in men over the age of 65. Initially, prostate cancer may be treated by surgery, removing the prostate gland, or by external beam radiation therapy or brachytherapy ("seeds" or "implants").

In some cases, the cancer becomes metastatic, spreading to other parts of the body. It is then usually treated by measures that modify the body's hormones, since prostate cancer cells are stimulated to grow by male hormones such as testosterone. However, the cancer may eventually become resistant to hormonal treatment and patients might then benefit from chemotherapy.

Docetaxel works by interfering with the cells' ability to divide. Currently used for some breast cancer and lung cancer patients, its side effects include changes in nails, tiredness, tingling and loss of sensation in fingers and toes. Docetaxel has been approved by the U.S. Food and Drug Administration.

This research was supported in part by Aventis, the company that manufactures Docetaxel.

Princess Margaret Hospital and its research arm, Ontario Cancer Institute, have achieved an international reputation as global leaders in the fight against cancer. Princess Margaret Hospital is a member of the University Health Network, which also includes Toronto General Hospital and Toronto Western Hospital. All three are teaching hospitals affiliated with the University of Toronto

Related articles

 

Use of aspirin or other NSAIDs increases survival for men with prostate cancer Oct 4, 2004

Cottonseed drug (Gossypol) boosts cancer treatment in mice Oct 5, 2004

Intermittent Taxotere/Calcitriol chemotherapy feasible in treatment of advanced prostate cancer. Treatment "holidays" may allow disease to be managed as chronic, rather then acute, condition. Oregon Health & Science University (OHSU), June 2003

Archive of stories about chemotherapy and prostate cancer (and related)

 

This article edited by J. Strax, Oct 5, 2004. Page last updated Nov 4, 2004.



advertising

 

Amonafide Phase I/II to treat Prostate Cancer: "What makes the new version of this old drug worth testing on men today?" trialbasis.com/forums Sept 27 2004

Wear blue Prostate Cancer Awareness ribbon! home · forums · news feed · links
About Us | Site Archive | Content Policy/Disclaimer | Privacy Policy
www. psa-rising.com © PSA Rising 1997-2004